Cleveland HeartLab

Cleveland HeartLab (CHL), LLC is a specialty clinical laboratory and disease management company focused on novel molecular biomarker technologies and the creation of proprietary diagnostic tests.

Cleveland HeartLab (CHL), LLC is a specialty clinical laboratory and disease management company focused on novel molecular biomarker technologies and the creation of proprietary diagnostic tests. The company operates a CAP-accredited and CLIA-certified Clinical Laboratory that receives samples from doctors’ offices and hospitals all across the country. CHL has developed a profile of tests that manage and reduce inflammation, a root cause of heart disease. In addition to its Inflammatory Profile, CHL has an array of tests that doctors can choose from.

Zapis Capital was an early investor in CHL, and participated on its board of directors until 2011.

One of the company’s proprietary tests, CardioMPO™, was cleared to market by the FDA in May 2005. The CardioMPO™ kit is an enzyme immunoassay intended for the quantitative determination of myeloperoxidase in human plasma. Kits are available for sale in the U.S. and Europe. CHL also runs a research & development laboratory where next-generation cardiovascular disease biomarkers are being developed for use in the clinical community. CHL has a significant pipeline of tests that are protected by exclusive intellectual property and target large, under-addressed markets. In addition, an agreement with the Cleveland Clinic provides the company access to intellectual property developed at the Clinic in the areas of cardiovascular and inflammatory biomarkers.

Status: Current Portfolio